ALLOAllogene Therapeutics
About Allogene Therapeutics
Allogene Therapeutics (NASDAQ:ALLO) is a biotechnology company focused on pioneering and advancing allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. With a robust pipeline of investigational therapies in various stages of development, Allogene aims to harness the power of the immune system to target and eradicate cancer cells. Their projects span across multiple cancer types, including both hematologic malignancies and solid tumors, with the objective of delivering transformative, readily available treatments. By leveraging cutting-edge technology and scientific research, Allogene is dedicated to improving patient outcomes and providing new hope in the fight against cancer.
What is ALLO known for?
Snapshot
Public US
Ownership
2017
Year founded
302
Employees
South San Francisco, United States
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
South San Francisco, US
Products and/or services of Allogene Therapeutics
- AlloCAR T therapy for cancer, leveraging engineered T-cells to target and eliminate tumor cells.
- Partnership on UCART19, an off-the-shelf CAR T-cell therapy for acute lymphoblastic leukemia.
- Advancements in AlloJoin for knee osteoarthritis, using allogeneic chondrocyte implantation techniques.
- Development of ALLO-715, aimed at treating multiple myeloma through a novel CAR T-cell approach.
- ALLO-501 and ALLO-501A, targeting non-Hodgkin's lymphoma with next-generation CAR T-cell therapies.
- Research into solid tumor treatments, exploring CAR T-cell strategies against traditionally challenging cancer types.
Allogene Therapeutics executive team
- Dr. Arie S. Belldegrun F.A.C.S., M.D.Co-Founder & Executive Chairman
- Dr. David D. Chang M.D., Ph.D.Co-Founder, President, CEO & Director
- Mr. Joshua A. KazamCo-Founder & Director
- Dr. Zachary J. Roberts M.D., Ph.D.Executive VP of Research & Development and Chief Medical Officer
- Mr. Geoffrey M. ParkerExecutive VP & CFO
- Mr. Benjamin M. BeneskiSenior VP & Chief Technical Officer
- Mr. Earl M. Douglas Esq.Senior VP, General Counsel, Compliance Officer & Corporate Secretary
- Ms. Susan R. LundeenChief People Officer
- Ms. Christine CassianoExecutive VP, Chief Corporate Affairs & Brand Strategy Officer
- Ms. Annie YoshiyamaSVP & Corporate Controller